{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-098860","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2024-08-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.800209+00:00","generated_at":"2026-05-31T08:30:12.687471+00:00","sec_items":["8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"PepGen appoints Paul Streck, M.D., MBA as EVP, Head of Research & Development","bullets":["Appoints Paul Streck, M.D., MBA as EVP, Head of R&D effective immediately, joining PepGen Executive Team.","Streck brings >20 yrs drug development experience; previously CMO at Albireo, Arena, Alder, Insmed, and roles at GSK, Shire, Amgen.","His accomplishments include five IND approvals, six global regulatory launches, nine commercial product launches.","CEO James McArthur cites Streck's value as PepGen advances four active clinical trials and preclinical pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-098860","json":"https://secwatch.observer/filing/0000950170-24-098860.json","markdown":"https://secwatch.observer/filing/0000950170-24-098860.md","text":"https://secwatch.observer/filing/0000950170-24-098860.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000095017024098860/0000950170-24-098860-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000095017024098860/pepg-20240820.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:30:12.687471+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}